DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX tria…

Biotechnology

US, Minneapolis [HQ]

Summary
IR
Fin. Reports
Financials
Leadership & Strategy
Possible Catalysts

Analysts
Dividend Payments
Government Awards
Insiders
Lobbying Expenses
Segment Revenues
Shareholder Structure
Supply / Portfolio
Valuation Models [Soon]

Lobbying Analysis

Lobbying · US Senate · Influence

Here you'll find all expenses made over the past 12M of DiaMedica Therapeutics Inc. to fulfill lobbying activities in the US.

DiaMedica Therapeutics Inc. has no lobbying expenses in our database.

History

Download

FY	Quarter	Expense For Lobby Disclosure	LDA Reference
No data